WAYNE, PA--(Marketwire - Apr 11, 2011) -
WHO:
Mollie Lombardi, senior research analyst, Human Capital Management for Aberdeen Group and Sunita Iyengar, product marketing manager at Kenexa (
WHAT:
Will discuss the findings from Aberdeen's March 2011 study titled "Onboarding, The Path to Productivity" during a complimentary webinar
WHEN:
Wednesday, April 20, 2011 at 1:00 p.m. ET (10:00 a.m. PT, 5:00 p.m. GMT)
WHERE:
Register for the webinar by accessing: http://intercallus.stream57.com/kenexa_042011/default.aspx?cid=kenexa
DETAILS:
Today's definition of onboarding is multi-faceted. It's about streamlined and efficient forms management, standardized and automated provisioning workflows, and most importantly, getting new employees engaged, excited and productive as quickly as possible. Drawing from Aberdeen's recent research on this business-critical topic, this webinar has been designed to help attendees learn key strategies that initiate or improve onboarding practices to reduce costs, improve engagement, and enhance organizational results through standardization, automation and innovative program delivery.
A copy of the Aberdeen study can be downloaded for a limited time by accessing: http://www.aberdeen.com/link/sponsor.asp?spid=30410099&cid=6923
About Kenexa
Kenexa® provides business solutions for human resources. We help global organizations multiply business success by identifying the best individuals for every job and fostering optimal work environments for every organization. For more than 20 years, Kenexa has studied human behavior and team dynamics in the workplace, and has developed the software solutions, business processes and expert consulting that help organizations impact positive business outcomes through HR. Kenexa is the only company that offers a comprehensive suite of unified products and services that support the entire employee lifecycle from pre-hire to exit. Additional information about Kenexa and its global products and services can be accessed at www.kenexa.com. Follow Kenexa on Twitter: @kenexa.